Lawrence G. Hamel, Chief Development Officer at ACELRX PHARMACEUTICALS INC (ACRX), bought 3,682 shares at $2.81 ($10K) on 2019-02-28, disclosed to the SEC on 2019-03-04.
Seasonal purchase ($10k) by Chief Development Officer — this insider has traded ACRX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| ACRX | SELL | 2017-10-03 | $108K | — | Filing → |